中华肝脏病杂志最新文献

{"title":"[Serum testosterone and estradiol levels correlate with disease severity and prognosis in male patients with liver failure].","authors":"Y Liu, S M Liu, H Li, H Q Tan, J Y Liu","doi":"10.3760/cma.j.cn501113-20240717-00331","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240717-00331","url":null,"abstract":"<p><p><b>Objective:</b> To investigate and explore the serum levels of testosterone and estradiol in correlation with disease severity and prognosis in male patients with liver failure. <b>Methods:</b> Sixty male cases with liver failure who received treatment from April 2022 to December 2023 were selected as the research subjects. Forty healthy subjects who underwent physical examination in the physical examination center during the same period were enrolled as the control group. The levels of sex hormones (serum testosterone and estradiol) were compared between the two groups. Logistic regression was used to analyze the diagnostic value of testosterone and estradiol for the grading of male patients with liver failure. The prognostic factors for predicting disease severity were analyzed using COX regression. The area under the ROC curve (AUC) was used to evaluate the predictive value. <b>Results:</b> The testosterone level was significantly higher in the healthy group than that in the liver failure group [(5.11±3.00) nmol/L vs. (2.22±2.78) nmol/L, <i>t</i>=4.934, <i>P</i><0.001], while the estradiol level was significantly lower in the liver failure group [37.46±13.21) nmol/L vs. (113.45±67.70) nmol/L, <i>t</i>=-8.457, <i>P</i><0.001]. Multiple discriminant logistic regression analysis results showed that estradiol and testosterone were independent predictors of the model for end-stage liver disease. Multivariate Cox regression analysis showed that testosterone was an independent prognostic factor for the 1-year mortality rate in male patients with liver failure. The area under the curve predicting the 1-year mortality rate was 0.745 after adjusting for other factors. <b>Conclusion:</b> Testosterone and estradiol levels are significantly altered in male patients with liver failure. Testosterone and estradiol levels in peripheral blood can effectively reflect the degree of liver function impairment and the 1-year mortality rate in male patients with liver failure, which is helpful for accurately assessing the severity of the disease and its prognosis.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 3","pages":"255-261"},"PeriodicalIF":0.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144015068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Analysis of clinical characteristics of inpatient cases with cryptogenic cirrhosis].","authors":"T T Ji, Y N Fan, Z Wang, M He, Y Y Yu, J H Xu","doi":"10.3760/cma.j.cn501113-20240411-00196","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240411-00196","url":null,"abstract":"<p><p><b>Objective:</b> To compare the clinical characteristics of patients with cryptogenic cirrhosis and hepatitis B cirrhosis in order to provide a basis for the diagnosis of cryptogenic cirrhosis. <b>Methods:</b> A retrospective study was performed. The clinical data of inpatients with cryptogenic cirrhosis from 2010 to 2020 were collected from Peking University First Hospital. The clinical baseline data were analyzed. Patients with hepatitis B cirrhosis hospitalized during the same period were used as the control group, and 1:1 matching was performed according to the age range (±5 years) and the same year of admission. The basic clinical data between the groups were analyzed. The t-test, X2-test or Mann-Whitney U test was used for intergroup comparison. <b>Results:</b> A total of 232 cases with cryptogenic cirrhosis were collected. A total of 207 cases were collected after excluding cases with missing data, including 95 males (45.9%) and 112 females (54.1%), with a median age of 66 (57-76) years. A total of 182 pairs were matched according to the matching criteria for the control study. Compared with the hepatitis B cirrhosis group, the patients with cryptogenic cirrhosis had higher blood triglycerides (0.89 mmol/L vs. 0.80 mmol/L, <i>P</i>=0.002)and total cholesterol (3.73 mmol/L vs. 3.55 mmol/L, <i>P</i>=0.048), alanine transaminase (21.0 U/L vs. 24.5 U/L, <i>P</i>=0.003) and aspartate transaminase (29.5 U/L vs. 33.0 U/L, <i>P</i>=0.008) were lower, the prothrombin time was shorter (12.4 s vs. 13.0 s, <i>P</i>=0.003), and the INR was lower (1.18 vs. 1.21, <i>P</i>=0.015) with statistically significant differences (<i>P</i><0.05). The proportion of patients with cryptogenic cirrhosis combined with hepatocellular carcinoma (15.9% vs. 35.7%, <i>P</i><0.001), hepatic encephalopathy (2.7% vs. 7.7%, <i>P</i>=0.034), and hepatorenal syndrome (1.6% vs. 5.5%, <i>P</i>=0.048),were relatively low, and the differences were statistically significant (<i>P</i><0.05). <b>Conclusions:</b> Cryptogenic cirrhosis at our hospital may be associated with metabolic syndrome and cannot be excluded as a cause of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in some of these patients.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 3","pages":"211-216"},"PeriodicalIF":0.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144000903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Study of a nomogram model of gadoxetate disodium-enhanced magnetic resonance imaging for the preoperative diagnosis of proliferative hepatocellular carcinoma and its value].","authors":"F X Chen, D J Guo, Y Xu, J Cheng, Y M Li, G L Chen, X M Li","doi":"10.3760/cma.j.cn501113-20240509-00246","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240509-00246","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To develop and explore the clinical value of a nomogram model for the preoperative diagnosis of proliferative hepatocellular carcinoma (HCC) based on gadoxetate disodium (Gd-EOB-DTPA) enhanced magnetic resonance imaging (MRI). &lt;b&gt;Methods:&lt;/b&gt; The preoperative Gd-EOB-DTPA-enhanced MRI data and clinical pathological data of patients with pathologically confirmed proliferative (178 cases) and non-proliferative type HCC (378 cases) from September 2017 to November 2022 were retrospectively collected. The MRI features and clinicopathological features of proliferative and non-proliferative type HCC were evaluated. Multivariate logistic regression analysis was used to determine the independent predictive factors of proliferative-type HCC. The nomogram prediction model was constructed using R software. The receiver operating characteristic curve (ROC) was used to evaluate its diagnostic efficacy. The calibration curve and decision curve analysis (DCA) were drawn to evaluate the calibration performance and clinical application value of the nomogram model. The optimal threshold for distinguishing high-risk from low-risk was determined using the Youden index. The survival prognosis of proliferative and non-proliferative type HCC was analyzed and compared using the Kaplan-Meier survival curve and the log-rank test. The measurement data were analyzed using the independent sample &lt;i&gt;t&lt;/i&gt;-test or the Mann-Whitney &lt;i&gt;U&lt;/i&gt; test. The count data were compared using the &lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt; test. &lt;b&gt;Results:&lt;/b&gt; There were statistically significant differences in alpha-fetoprotein (AFP) levels (&lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=17.244, &lt;i&gt;P&lt;/i&gt;&lt;0.001), tumor morphology (&lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=13.669, &lt;i&gt;P&lt;/i&gt;&lt;0.001), intratumoral fatty degeneration (&lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=10.495, &lt;i&gt;P&lt;/i&gt;=0.001), abnormal enhancement of peritumoral abnormalities during arterial phase (&lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=37.662, &lt;i&gt;P&lt;/i&gt;&lt;0.001), tumor capsule (&lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=23.961, &lt;i&gt;P&lt;/i&gt;&lt;0.001), intratumoral necrosis (&lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=77.184,&lt;i&gt;P&lt;/i&gt;&lt;0.001), intratumoral hemorrhage (&lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=4.892,&lt;i&gt;P&lt;/i&gt;=0.027), peritumoral hypointense in hepatobiliary phase (&lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=47.675,&lt;i&gt;P&lt;/i&gt;&lt;0.001), rim arterial phase hyperenhancement (&lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=115.976,&lt;i&gt;P&lt;/i&gt;&lt;0.001), intratumoral artery (&lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=15.528,&lt;i&gt;P&lt;/i&gt;&lt;0.001) and intravenous tumor thrombus (&lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=10.532,&lt;i&gt;P&lt;/i&gt;=0.001) between proliferative and non-proliferative type HCC groups. Multivariate logistic regression analysis showed that AFP&gt;200 μg/L (&lt;i&gt;OR&lt;/i&gt;=1.561, &lt;i&gt;P&lt;/i&gt;=0.044), no intratumoral fatty degeneration (&lt;i&gt;OR&lt;/i&gt;=1.947, &lt;i&gt;P&lt;/i&gt;=0.033), intratumoral necrosis (&lt;i&gt;OR&lt;/i&gt;=2.084, &lt;i&gt;P&lt;/i&gt;=0.003), peritumoral hypointensity in the hepatobiliary phase (&lt;i&gt;OR&lt;/i&gt;=2.314, &lt;i&gt;P&lt;/i&gt;=0.001), and annular hyperenhancement in the arterial phase (&lt;i&gt;OR&lt;/i&gt;=5.557, &lt;i&gt;P&lt;/i&gt;&lt;0.001) were independent predictors for preoperative diagnosis of proliferative-type HCC. A nom","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 3","pages":"227-236"},"PeriodicalIF":0.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144039928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Research progress on the involvement of exosome-mediated intercellular communication in the remodeling and the regulation of invasion and metastasis in the hepatocellular tumor microenvironment].","authors":"K Q Zhong, W H Ren, T Li","doi":"10.3760/cma.j.cn501113-20230920-00114","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20230920-00114","url":null,"abstract":"<p><p>Hepatocellular carcinoma (referred to as liver cancer) tumor microenvironment (TMEs) is a dynamic network system composed of stromal cells, such as liver cancer cells, immune cells, vascular endothelial cells, adipocytes, fibroblasts, and various cytokines that play an important role in the invasion and metastasis of liver cancer. In recent years, there has been an increasing attention on the role of exosomes in the remodeling and the regulation of invasion and metastasis in liver cancer TMEs. Exosomes, as a natural carrier, mediate intercellular communication between liver cancer cells and with other stromal cells, playing an important role in the formation of immunosuppressive TMEs, angiogenesis and hypoxia tolerance, and the coordination of heterogeneity among liver cancer cells. This review summarizes the composition of liver cancer TMEs, the biological functions of exosomes, and the role and mechanism of exosome-mediated liver cancer TMEs between liver cancer cells and other stromal cells, with a focus on exosome involvement in the remodeling and regulating invasion and metastasis in liver cancer TMEs. Simultaneously, it also introduces and explores the application of exosomes in the diagnosis and treatment of liver cancer, with the hope that in-depth research and elucidation of the mechanisms of exosome involvement in the remodeling and regulation of invasion and metastasis in liver cancer TMEs will provide feasible research ideas for novel biological markers and drug delivery carriers.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 3","pages":"280-286"},"PeriodicalIF":0.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144049838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Interactions between common drug metabolism and precautions for drug usage in Gilbert syndrome].","authors":"D C Dacheng, C Liang, S J Zheng","doi":"10.3760/cma.j.cn501113-20230921-00115","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20230921-00115","url":null,"abstract":"<p><p>Gilbert's syndrome is a type of hereditary disease caused by mutations in the uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) gene, which leads to decreased UGT1A1 activity. Clinically, it is mainly characterized by increased unconjugated bilirubin and is often considered a benign disease. The incidence rate of Gilbert's syndrome is as high as 5%-10% in the population, and its interaction with commonly used clinical drugs deserves attention. On the one hand, some drugs can enhance or reduce UGT1A1 activity, causing bilirubin levels to decrease or increase. On the other hand, the decrease of UGT1A1 activity can also change part of drug metabolism, increase or reduce drug efficacy, and may cause adverse reactions and even endanger the patient's life in severe conditions. This article summarizes the interactions between common drug metabolism and precautions for drug usage in Gilbert syndrome.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 3","pages":"293-299"},"PeriodicalIF":0.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144052674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Wilson's disease misdiagnosed as autoimmune hepatitis: a case report and literature review].","authors":"L F Chen, Y P Wan, L M Xiao, D Li, Z L Wen, L L Yang","doi":"10.3760/cma.j.cn501113-20240411-00193","DOIUrl":"10.3760/cma.j.cn501113-20240411-00193","url":null,"abstract":"","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 ","pages":"262-266"},"PeriodicalIF":0.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142629100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Exploring the relationship between alcohol intake and all-cause mortality in participants with MASLD and MetALD: a study based on NHANES III data].","authors":"L Y Jia, F J Rui, X Y Wu, S S Zhou, Y J Chen, C Wu, J P Shi, W H Wu, J Li","doi":"10.3760/cma.j.cn501113-20241018-00547","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20241018-00547","url":null,"abstract":"<p><p><b>Objective:</b> To evaluate the association between different levels of alcohol intake and all-cause mortality in metabolic dysfunction-associated steatotic liver disease（MASLD）and alcohol-related/associated liver disease（MetALD）<b>.</b> <b>Method:</b> This study included participants aged 20 to 74 who were diagnosed with hepatic steatosis by ultrasound. The data were derived from the Third National Health and Nutrition Examination Survey（NHANES Ⅲ）conducted in the United States from 1988 to 1994. Multivariable-adjusted hazard ratios（aHR）and their 95% confidence intervals（CI）were calculated by Cox proportional risk regression modelling to assess the effect of alcohol consumption levels on all-cause mortality. Participants were categorized into three groups based on daily alcohol intake：low，moderate，and high consumption groups. <b>Results:</b> A total of 2 322 participants were included，with 50.2% males（1 166/2 322），and median age 42.0（31.3-57.0）years. During a median follow up of 316.0（270.0-337.0）months，the overall mortality rate was 1.48% per person-year. The all-cause mortality were 1.38%，1.67% and 2.10% per person-year for those participants in three alcohol intake groups. After adjusting for covariates，daily moderate alcohol intake group（adjusted hazard ratio［aHR］=1.37，95% <i>CI</i> 1.12-1.67，<i>P</i>=0.002），and daily high alcohol intake group（aHR=1.45，95% <i>CI</i> 1.17-1.80，<i>P</i>=0.001），were independently associated with increased all-cause mortality. In subgroup analysis by diabetes status and age，there were significant differences in all-cause mortality across various levels of alcohol intake among non-type 2 diabetes mellitus（T2DM）participants under 60 years old，but not among non-T2DM participants over 60 years old，and T2DM participants of all ages. <b>Conclusion:</b> Alcohol intake has a dose-dependent negative impact on MASLD and MetALD patients. The risk of all-cause mortality significantly increases with higher alcohol intake. To evaluate the association between different levels of alcohol intake and all-cause mortality in metabolic dysfunction-associated steatotic liver disease（MASLD）and alcohol-related/associated liver disease（MetALD）.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"28 ","pages":"1-10"},"PeriodicalIF":0.0,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143587491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Research progress on the mechanistic role and constituents of hepatic macrophages during the occurrence and development of hepatic fibrosis].","authors":"R X Liu, J F Liu, P Xu","doi":"10.3760/cma.j.cn501113-20240103-00006","DOIUrl":"10.3760/cma.j.cn501113-20240103-00006","url":null,"abstract":"<p><p>Macrophages are the key cells in the process of hepatic fibrosis. Therefore, they promote the progression and regression of liver fibrosis by participating in all stages. The treatment of liver fibrosis is significantly identified by the main subtypes of intrahepatic macrophages. This article summarizes the types and functions of macrophages according to the inflammatory phenotype, origin, and surface markers and their effect on fibrosis; introduces the new subtypes and mode of action in the occurrence and development of hepatic fibrosis, as revealed by the single-cell sequencing technique; and analyzes the limitations of traditional antifibrotic therapy and the advantages of macrophage-targeting therapeutics, which could indicate the new direction for the study of new macrophage subtypes in hepatic fibrosis.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 2","pages":"198-204"},"PeriodicalIF":0.0,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143568423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Analysis of <i>PIKFYVE</i> gene expression, clinical significance, and experimental validation based on TCGA database in hepatocellular carcinoma].","authors":"L M Wen, Y L Guo, D X Zheng, Q Hou, W Dai, X Gao, J H Yang","doi":"10.3760/cma.j.cn501113-20240402-00168","DOIUrl":"10.3760/cma.j.cn501113-20240402-00168","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To experimentally validate clinical samples, analyze the mRNA expression of the FYVE domain containing phosphatidylinositol 3-phosphate 5 kinase (&lt;i&gt;PIKFYVE&lt;/i&gt;) gene, and its clinical significance based on the Cancer Genome Atlas (TCGA) database in hepatocellular carcinoma (HCC). &lt;b&gt;Methods:&lt;/b&gt; Data information on 424 clinical samples (including 374 cases of HCC tissues and 50 cases of non-tumorous liver tissues) were collected based on the TCGA database. Cox regression analysis and the Kaplan-Meier method were used to analyze the relationship between mRNA expression of the &lt;i&gt;PIKFYVE&lt;/i&gt; gene and the clinical characteristics as well as survival prognosis in patients with HCC. The relationship between the &lt;i&gt;PIKFYVE&lt;/i&gt; gene and immune cell infiltration was examined by correlation analysis with 24 kinds of immune cells. In addition, the mRNA expression level of the &lt;i&gt;PIKFYVE&lt;/i&gt; gene and RAC-alpha serine/threonine-protein kinase (&lt;i&gt;AKT1&lt;/i&gt;), phosphatase and tensin homolog (&lt;i&gt;PTEN&lt;/i&gt;), protein kinase C alpha (&lt;i&gt;PRKCA&lt;/i&gt;), inositol polyphosphate-5-phosphatase (&lt;i&gt;INPP5D&lt;/i&gt;), phosphoinositide-3-kinase regulatory subunit 1 (&lt;i&gt;PIK3R1&lt;/i&gt;), inositol polyphosphate 4-phosphatase type II (&lt;i&gt;INPP4B&lt;/i&gt;) and phospholipase C beta 4 (&lt;i&gt;PLCB4&lt;/i&gt;) gene correlations were analyzed in HCC tissues. At the same time, paraffin sections of highly differentiated, moderately differentiated, poorly differentiated, and non-tumor liver tissues from patients with HCC were collected from the Department of Pathology of the First Affiliated Hospital of Xinjiang Medical University. The histopathological observation was performed by HE staining. Immunohistochemistry was used to verify the expression levels of the PIKFYVE and Ki67 proteins in each clinical sample. The t-test was used for intergroup comparison of continuous data. The &lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt; test and Wilcoxon rank sum test were used for intergroup comparison of enumeration data. The Kaplan-Meier method was used for survival analysis. &lt;b&gt;Results:&lt;/b&gt; The expression level of the &lt;i&gt;PIKFYVE&lt;/i&gt; gene was higher in the HCC tumor than that in normal liver tissue (&lt;i&gt;P&lt;/i&gt;&lt;0.01). The overall survival time of patients was significantly longer in the low expression group than that in the high expression group (&lt;i&gt;HR&lt;/i&gt;=1.57, 95%&lt;i&gt;CI&lt;/i&gt;: 1.10～2.25, &lt;i&gt;P&lt;/i&gt;=0.014). The results of univariate Cox regression analysis showed that tumor stage, pathological grade, tumor status, residual tumor, and &lt;i&gt;PIKFYVE&lt;/i&gt; expression level all had an effect on OS (&lt;i&gt;P&lt;/i&gt;&lt;0.05). The PIKFYVE prognostic risk model had a proportionate score of &lt;i&gt;HR&lt;/i&gt;=1.533 (95%&lt;i&gt;CI&lt;/i&gt;: 1.077～2.181, &lt;i&gt;P&lt;/i&gt;=0.018). Multivariate Cox risk regression analysis showed that the PIKFYVE prognostic risk model had a proportionate score of &lt;i&gt;HR&lt;/i&gt;=1.481 (95%&lt;i&gt;CI&lt;/i&gt;: 0.886～2.476, &lt;i&gt;P&lt;/i&gt;=0.134) and an area under the receiver operating characteristic curve of 0.559, indicating that it had predictive value for survival predic","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 ","pages":"159-169"},"PeriodicalIF":0.0,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142629210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Analysis of the results of the Fuxing Program Action for micro-elimination of hepatitis C in Zhuhai].","authors":"X C Zheng, M D Ou, Y Li, Y Q Zou, L D Qiu, Z S Hong, J Y Xia","doi":"10.3760/cma.j.cn501113-20240224-00091","DOIUrl":"10.3760/cma.j.cn501113-20240224-00091","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; The Fuxing Program was established in Zhuhai as an action plan to micro-eliminate hepatitis C in response to the World Health Organization's goal of eliminating hepatitis C by 2030. Therefore, the effectiveness of this program in terms of hepatitis C screening, treatment, follow-up, and other aspects is evaluated here. &lt;b&gt;Methods:&lt;/b&gt; The \"Fuxing Project\" was established in May 2021 under the supervision of the Zhuhai Medical Quality Control Center for Infectious Diseases. A bridge was formed among the governmental entities, hospitals at all levels, and the community to train hepatitis C prevention and control strategies. Hepatitis C screening, publicity, and educational awareness were conducted in-and out-of-hospital. The responsibility for the diagnosis, treatment, and follow-up of a patient with hepatitis C was assigned to the staff. The screening and treatment rates of hepatitis C in hospitals before and after the initiation of the project were compared and analyzed using the &lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt; test or Fisher's exact test. The hepatitis C virus (HCV) infection and treatment status were investigated and analyzed among the general population, high-risk populations such as human immunodeficiency virus (HIV) infection, drug addicts, and the population residing in supervised sites within Zhuhai communities, rural areas, schools, or factories. &lt;b&gt;Results:&lt;/b&gt; Anti-HCV positivity rate (0.82% vs. 0.43%, &lt;i&gt;P&lt;/i&gt;&lt;0.001), HCV RNA detection rate (98.1% vs. 59.5%, &lt;i&gt;P&lt;/i&gt;&lt;0.001), HCV RNA detection positivity rate (52.56% vs. 29.76%, &lt;i&gt;P&lt;/i&gt;&lt;0.001), HCV RNA positivity rate (0.4% vs. 0.13%, &lt;i&gt;P&lt;/i&gt;&lt;0.001), and hepatitis C treatment rate (76.76% vs. 31.97%, &lt;i&gt;P&lt;/i&gt;&lt;0.001) were significantly higher among the inpatient population after the Fuxing Program initiation than before. The HCV RNA detection rate (58.52% vs. 6.93%, &lt;i&gt;P&lt;/i&gt;&lt;0.001) and HCV RNA detection positivity rate (77.72% vs. 29.41%, &lt;i&gt;P&lt;/i&gt;&lt;0.001) in Zhuhai were significantly higher after the Fuxing Program initiation than before. Anti-HCV positivity rate (0.46% vs. 1.28%, &lt;i&gt;P&lt;/i&gt;=0.009) and HCV RNA (0.32% vs. 0.99%, &lt;i&gt;P&lt;/i&gt;=0.03) were significantly lower in the Zhuhai general population of urban communities than those of the general population in rural areas. The HCV infection rate was more than three times higher in rural populations than in urban populations. Anti-HCV positivity rate, HCV RNA positivity rate, HCV RNA detection positivity rate, and hepatitis C treatment rates were 2.64% (31/1 175), 3.40% (69/2 022) and 94.4% (34/36), 2.64% (31/1 175), 2.72% (55/2 022), 50.00% (18/36), and 100% (31/31), 79.71% (55/69) and 52.94% (18/34), and 100% (31/31), 0 (0/55) and 55.55% (10/18) among the HIV infection, supervised population under supervised sites, and methadone maintenance treatment clinic population, respectively. Anti-HCV positivity rate (4.15% vs. 0.72%, &lt;i&gt;P&lt;/i&gt;&lt;0.001) and HCV RNA (3.22% vs. 0.53%, &lt;i&gt;P&lt;/i&gt;&lt;0.001) were significantly higher in the high-ri","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"33 2","pages":"135-142"},"PeriodicalIF":0.0,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143568259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}